Diabetes Metab J.  2016 Oct;40(5):376-385. 10.4093/dmj.2016.40.5.376.

Statins Increase Mitochondrial and Peroxisomal Fatty Acid Oxidation in the Liver and Prevent Non-Alcoholic Steatohepatitis in Mice

• Park HS
• Jang JE
• Ko MS
• Woo SH
• Kim BJ
• Kim HS
• Park HS
• Park IS
• Koh EH
• Lee KU

• KMID: 2354611
• DOI: http://doi.org/10.4093/dmj.2016.40.5.376

Abstract

BACKGROUND
Non-alcoholic fatty liver disease is the most common form of chronic liver disease in industrialized countries. Recent studies have highlighted the association between peroxisomal dysfunction and hepatic steatosis. Peroxisomes are intracellular organelles that contribute to several crucial metabolic processes, such as facilitation of mitochondrial fatty acid oxidation (FAO) and removal of reactive oxygen species through catalase or plasmalogen synthesis. Statins are known to prevent hepatic steatosis and non-alcoholic steatohepatitis (NASH), but underlying mechanisms of this prevention are largely unknown.
METHODS
Seven-week-old C57BL/6J mice were given normal chow or a methionine- and choline-deficient diet (MCDD) with or without various statins, fluvastatin, pravastatin, simvastatin, atorvastatin, and rosuvastatin (15 mg/kg/day), for 6 weeks. Histological lesions were analyzed by grading and staging systems of NASH. We also measured mitochondrial and peroxisomal FAO in the liver.
RESULTS
Statin treatment prevented the development of MCDD-induced NASH. Both steatosis and inflammation or fibrosis grades were significantly improved by statins compared with MCDD-fed mice. Gene expression levels of peroxisomal proliferator-activated receptor α (PPARα) were decreased by MCDD and recovered by statin treatment. MCDD-induced suppression of mitochondrial and peroxisomal FAO was restored by statins. Each statin's effect on increasing FAO and improving NASH was independent on its effect of decreasing cholesterol levels.
CONCLUSION
Statins prevented NASH and increased mitochondrial and peroxisomal FAO via induction of PPARα. The ability to increase hepatic FAO is likely the major determinant of NASH prevention by statins. Improvement of peroxisomal function by statins may contribute to the prevention of NASH.

Keyword

Fatty acid oxidation; Non-alcoholic fatty liver disease; Peroxisomes; Statins

MeSH Terms

Animals
Atorvastatin Calcium
Catalase
Cholesterol
Developed Countries
Diet
Fatty Liver*
Fibrosis
Gene Expression
Hydroxymethylglutaryl-CoA Reductase Inhibitors*
Inflammation
Liver Diseases
Liver*
Metabolism
Mice*
Non-alcoholic Fatty Liver Disease
Organelles
Peroxisomes
Pravastatin
Reactive Oxygen Species
Rosuvastatin Calcium
Simvastatin
Atorvastatin Calcium
Catalase
Cholesterol
Pravastatin
Reactive Oxygen Species
Rosuvastatin Calcium
Simvastatin

Figure

• 

  Fig. 1 Statin treatment attenuates methionine- and choline-deficient diet (MCDD)-induced hepatic steatosis and steatohepatitis. Representative histological images of each experimental group. H&E (×200; scale bar=100 µm), MT (×100; scale bar=50 µm). ND, normal chow diet; MT, Masson's trichrome.

• 

  Fig. 2 Histologic scores and hepatic triglyceride (TG) content and plasma alanine aminotransferase (ALT) level. (A) Histologic scores for location and severity of steatosis, inflammation, and fibrosis, according to criteria of Kleiner et al. [18]. (B) Hepatic TG content and plasma ALT level in mice fed normal chow diet (ND) and methionine- and choline-deficient diet (MCDD) with or without various statins for 6 weeks. F, fluvastatin; P, pravastatin; S, simvastatin; A, atorvastatin; R, rosuvastatin. aP<0.05 compared with ND, bP<0.05 compared with MCDD.

• 

  Fig. 3 Treatment with statins recovers methionine- and choline-deficient diet (MCDD)-induced suppression of peroxisomal proliferator-activated receptor α (PPARα) and target gene expression levels in the liver. (A) mRNA expression levels and (B) protein expression levels of PPARα. Expression levels of genes involved in mitochondrial and peroxisomal (C) fatty acid oxidation (FAO), and (D) peroxisomal biogenesis factor (Pex) 7. ND, normal chow diet; F, fluvastatin; P, pravastatin; S, simvastatin; A, atorvastatin; R, rosuvastatin; CPT, carnitine palmitoyltransferase; ACOX, acyl CoA oxidase; DBP, D-bifunctional protein. aP<0.05 compared with ND, bP<0.05 compared with MCDD.

• 

  Fig. 4 Measurement of hepatic fatty acid oxidation (FAO) in mice fed methionine- and choline-deficient diet (MCDD) with or without statins. (A) Mitochondrial FAO. (B) Peroxisomal FAO. DPM, disintegrations per minute; ND, normal chow diet; F, fluvastatin; P, pravastatin; S, simvastatin; A, atorvastatin; R, rosuvastatin. aP<0.05 compared with ND, bP<0.05 compared with MCDD.

• 

  Fig. 5 Changes in hepatic lipid peroxidation and gene expression levels of several anti-oxidative enzymes. (A) Hepatic malondialdehyde (MDA) levels in mice fed methionine- and choline-deficient diet (MCDD) and fluvastatin supplementation. (B) mRNA expression levels of catalase, (C) manganese superoxide dismutase (MnSOD), and (D) glutathione peroxidase 1 (GPx-1). ND, normal chow diet; F, fluvastatin; P, pravastatin; S, simvastatin; A, atorvastatin. aP<0.05 compared with ND, bP<0.05 compared with MCDD.

Reference

1. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006; 43:2 Suppl 1. S99–S112.

2. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011; 140:124–131.

3. Yoo HJ, Choi KM. Hepatokines as a link between obesity and cardiovascular diseases. Diabetes Metab J. 2015; 39:10–15.

4. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004; 40:1387–1395.

5. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010; 28:155–161.

6. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004; 109:23 Suppl 1. III39–III43.

7. Rodriguez-Calvo R, Barroso E, Serrano L, Coll T, Sanchez RM, Merlos M, Palomer X, Laguna JC, Vázquez-Carrera M. Atorvastatin prevents carbohydrate response element binding protein activation in the fructose-fed rat by activating protein kinase A. Hepatology. 2009; 49:106–115.

8. Landrier JF, Thomas C, Grober J, Duez H, Percevault F, Souidi M, Linard C, Staels B, Besnard P. Statin induction of liver fatty acid-binding protein (L-FABP) gene expression is peroxisome proliferator-activated receptor-alpha-dependent. J Biol Chem. 2004; 279:45512–45518.

9. Moreno M, Ramalho LN, Sancho-Bru P, Ruiz-Ortega M, Ramalho F, Abraldes JG, Colmenero J, Dominguez M, Egido J, Arroyo V, Ginès P, Bataller R. Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver. Am J Physiol Gastrointest Liver Physiol. 2009; 296:G147–G156.

10. Trebicka J, Hennenberg M, Odenthal M, Shir K, Klein S, Granzow M, Vogt A, Dienes HP, Lammert F, Reichen J, Heller J, Sauerbruch T. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J Hepatol. 2010; 53:702–712.

11. Mari M, Caballero F, Colell A, Morales A, Caballeria J, Fernandez A, Enrich C, Fernandez-Checa JC, Garcia-Ruiz C. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab. 2006; 4:185–198.

12. Grattagliano I, de Bari O, Bernardo TC, Oliveira PJ, Wang DQ, Portincasa P. Role of mitochondria in nonalcoholic fatty liver disease: from origin to propagation. Clin Biochem. 2012; 45:610–618.

13. Hall D, Poussin C, Velagapudi VR, Empsen C, Joffraud M, Beckmann JS, Geerts AE, Ravussin Y, Ibberson M, Oresic M, Thorens B. Peroxisomal and microsomal lipid pathways associated with resistance to hepatic steatosis and reduced pro-inflammatory state. J Biol Chem. 2010; 285:31011–31023.

14. Peeters A, Swinnen JV, Van Veldhoven PP, Baes M. Hepatosteatosis in peroxisome deficient liver despite increased β-oxidation capacity and impaired lipogenesis. Biochimie. 2011; 93:1828–1838.

15. Imoto Y, Kuroiwa H, Yoshida Y, Ohnuma M, Fujiwara T, Yoshida M, Nishida K, Yagisawa F, Hirooka S, Miyagishima SY, Misumi O, Kawano S, Kuroiwa T. Single-membrane-bounded peroxisome division revealed by isolation of dynamin-based machinery. Proc Natl Acad Sci U S A. 2013; 110:9583–9588.

16. Wanders RJ, Waterham HR. Peroxisomal disorders: the single peroxisomal enzyme deficiencies. Biochim Biophys Acta. 2006; 1763:1707–1720.

17. Antonenkov VD, Grunau S, Ohlmeier S, Hiltunen JK. Peroxisomes are oxidative organelles. Antioxid Redox Signal. 2010; 13:525–537.

18. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41:1313–1321.

19. Kim JY, Koves TR, Yu GS, Gulick T, Cortright RN, Dohm GL, Muoio DM. Evidence of a malonyl-CoA-insensitive carnitine palmitoyltransferase I activity in red skeletal muscle. Am J Physiol Endocrinol Metab. 2002; 282:E1014–E1022.

20. Caballero F, Fernandez A, Matias N, Martinez L, Fucho R, Elena M, Caballeria J, Morales A, Fernandez-Checa JC, Garcia-Ruiz C. Specific contribution of methionine and choline in nutritional nonalcoholic steatohepatitis: impact on mitochondrial S-adenosyl-L-methionine and glutathione. J Biol Chem. 2010; 285:18528–18536.

21. Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, Petricoin EF, Liotta LA, Winters M, Benz S, Benz CC. Breast cancer growth prevention by statins. Cancer Res. 2006; 66:8707–8714.

22. Rodrigues TA, Alencastre IS, Francisco T, Brites P, Fransen M, Grou CP, Azevedo JE. A PEX7-centered perspective on the peroxisomal targeting signal type 2-mediated protein import pathway. Mol Cell Biol. 2014; 34:2917–2928.

23. Serviddio G, Giudetti AM, Bellanti F, Priore P, Rollo T, Tamborra R, Siculella L, Vendemiale G, Altomare E, Gnoni GV. Oxidation of hepatic carnitine palmitoyl transferase-I (CPT-I) impairs fatty acid beta-oxidation in rats fed a methionine-choline deficient diet. PLoS One. 2011; 6:e24084.

24. Jorgacevic B, Mladenovic D, Ninkovic M, Prokic V, Stankovic MN, Aleksic V, Cerovic I, Vukicevic RJ, Vucevic D, Stankovic M, Radosavljevic T. Dynamics of oxidative/nitrosative stress in mice with methionine-choline-deficient diet-induced nonalcoholic fatty liver disease. Hum Exp Toxicol. 2014; 33:701–709.

25. Margaritis M, Channon KM, Antoniades C. Statins as regulators of redox state in the vascular endothelium: beyond lipid lowering. Antioxid Redox Signal. 2014; 20:1198–1215.

26. Day CP. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol. 2002; 16:663–678.

27. Reddy JK, Hashimoto T. Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annu Rev Nutr. 2001; 21:193–230.

28. Islinger M, Grille S, Fahimi HD, Schrader M. The peroxisome: an update on mysteries. Histochem Cell Biol. 2012; 137:547–574.

29. Van Veldhoven PP. Biochemistry and genetics of inherited disorders of peroxisomal fatty acid metabolism. J Lipid Res. 2010; 51:2863–2895.

30. Lopez-Erauskin J, Galino J, Ruiz M, Cuezva JM, Fabregat I, Cacabelos D, Boada J, Martinez J, Ferrer I, Pamplona R, Villarroya F, Portero-Otin M, Fourcade S, Pujol A. Impaired mitochondrial oxidative phosphorylation in the peroxisomal disease X-linked adrenoleukodystrophy. Hum Mol Genet. 2013; 22:3296–3305.

31. Baumgart E, Vanhorebeek I, Grabenbauer M, Borgers M, Declercq PE, Fahimi HD, Baes M. Mitochondrial alterations caused by defective peroxisomal biogenesis in a mouse model for Zellweger syndrome (PEX5 knockout mouse). Am J Pathol. 2001; 159:1477–1494.

32. Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med. 2012; 52:59–69.

33. Shishehbor MH, Brennan ML, Aviles RJ, Fu X, Penn MS, Sprecher DL, Hazen SL. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation. 2003; 108:426–431.

34. Yilmaz MI, Baykal Y, Kilic M, Sonmez A, Bulucu F, Aydin A, Sayal A, Kocar IH. Effects of statins on oxidative stress. Biol Trace Elem Res. 2004; 98:119–127.

35. Braverman NE, Moser AB. Functions of plasmalogen lipids in health and disease. Biochim Biophys Acta. 2012; 1822:1442–1452.

36. Wallner S, Schmitz G. Plasmalogens the neglected regulatory and scavenging lipid species. Chem Phys Lipids. 2011; 164:573–589.

37. Lewis JH. Clinical perspective: statins and the liver: harmful or helpful? Dig Dis Sci. 2012; 57:1754–1763.

38. Bjornsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol. 2012; 56:374–380.

39. Athyros VG, Tziomalos K, Gossios TD, Griva T, Anagnostis P, Kargiotis K, Pagourelias ED, Theocharidou E, Karagiannis A, Mikhailidis DP. GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 2010; 376:1916–1922.

40. Eslami L, Merat S, Malekzadeh R, Nasseri-Moghaddam S, Aramin H. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Cochrane Database Syst Rev. 2013; 12:CD008623.